As we begin the new year, we reflect on the challenges faced by the biotech sector over the past two years. Despite those challenges, we have the pleasure to report on TransCode’s progress and ...
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA ...
TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...
Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months ...
BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...
TransCode Therapeutics Inc. (RNAZ) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...
Hosted on MSN
TransCode announces collaboration for phase 2a trial
TransCode Therapeutics ( (RNAZ)) has shared an announcement. On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead ...
The MarketWatch News Department was not involved in the creation of this content. -- TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences -- Concurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results